Egalet Stock Price (NASDAQ:EGLT)

Add to My Stocks
$5.02 $0.22 (4.2%) EGLT stock closing price Jan 20, 2017 (Closing)
YOUR DAILY UPDATE ON
EGLT
Egalet
20 JAN 2017
amigobulls logo
EGLT hand_up
EGLT vs S&P 500
Closing Price: Jan 20, 2017
EGLT
$5.02 ( -4.2%)
S&P 500
2271.3 ( 0.34%)
EGLT
52 Week Price Range
1 Year Return: -35.23%
Q3 Growth*
Excellent
Profitable ?
No
net image
2016 Q3 Net Loss
-251.9%
home image
Rating
EGLT POOR
☆ ☆ ☆ ☆ ☆★ ★ ★ ★ ★
Double Tap To Exit Full Screen
0:00
/

Egalet Snapshot Video

13 5 2

EGLT Stock Details

Prev Close* : $5.24
Market Cap:
$131.99M
Day Low: $5
52 Week Low: $4.34
Open: $5.24
Volume: 631156
Day High: $5.26
52 Week High: $10.00
Dividend:
N/A

Latest Stock Market News

Latest Articles

Egalet News - From Partners

EGLT Stockcharts

View EGLT PE ratio, PS ratio stocks charts and compare with peers.
EGLT Chart
Note: Compare Egalet stock price history with the index and industry peers.

Egalet Valuation

PS ratio (
price to sales ratio
)
4.08
PB ratio (
price to book ratio
)
1.84

Egalet Financial Ratios

Asset Turnover
0.14
Receivables Turnover
12.06
Debt to Equity
3.22

EGLT Industry Peers

Company Price Change (%)
Immune Design (IMDZ)5.450.1 (1.87%)
Arrowhead Pharma (ARWR)1.820.02 (1.09%)
Acura Pharma (ACUR)0.60.03 (5.26%)
Collegium Pharma (COLL)14.950.19 (1.29%)
Kempharma (KMPH)3.250.05 (1.52%)
Acelrx Pharma (ACRX)2.650.05 (1.85%)
Nektar Therapeutics (NKTR)12.020.23 (1.88%)

Top Stock Gainers

show top losers
CompanyPriceChange (%)
Aralez Pharma (ARLZ)4.40.34 (8.37%)
Concert Pharma (CNCE)9.370.52 (5.88%)
AVADEL PHARMA (AVDL)10.310.4 (4.04%)
Nutraceutical International (NUTR)34.80.4 (1.16%)
Aratana Therapeutics (PETX)7.620.08 (1.06%)
La Jolla Pharma (LJPC)20.130.2 (1%)
Zoetis (ZTS)53.970.47 (0.88%)
Top gainers from Medical-Drugs industry
* As of Jan 21, 2017
CompanyPriceChange (%)
Synergy Pharma (SGYP)5.910.5 (7.8%)
Achaogen (AKAO)17.551.29 (6.85%)
Cempra (CEMP)30.2 (6.25%)
Xencor (XNCR)21.741.01 (4.44%)
Endo International (ENDP)12.340.56 (4.34%)
Egalet (EGLT)5.020.22 (4.2%)
Durect (DRRX)1.180.05 (4.07%)
Top losers from Medical-Drugs industry
* As of Jan 21, 2017

Egalet Financial Statements

income statement20152014201320122011
Net Sales Or Revenues22.83M1.92M-1.2M0.62M
Net Income-57.93M-43.21M-20.2M-5.39M-6.45M
Total Operating Expense71.76M39.05M11.15M6.49M6.52M
view Egalet Corp income statement
balance sheet20152014201320122011
Total Assets172.41M60.57M20.36M5.59M2.09M
Total Liabilities83.19M16.3M30.23M1.93M6.99M
Shareholders Equity89.22M44.26M-9.87M3.65M-7.11M
view Egalet Corp balance sheet
cash flow statement20152014201320122011
Net Increase (Decrease) In Assets Liabilities7M1.98M10.13M-0.46M0.02M
Net Cash From (Used By) Operating Activities-38.9M-25.07M-0.43M-5.46M-5.46M
Increase (Decrease) In Prop Plant And Equipment-2.74M-2.88M-1.79M-0.31M-0.17M
view Egalet Corp cashflow statement

Egalet Corp Stock News - Partner Headlines

Egalet Stock Message Board

An investor needs to spend 5.02 to buy EGLT stock, as the closing Egalet stock price is 5.02. Egalet market capitalization is 131.99M and it represents the total market value of EGLT stock. A value investor must look at the fundamentals of a stock, and perform Egalet valuation, even though in the short-term sentiment and current breaking news might affect Egalet stock price.

The stock price movement of a company indicates what investors are willing to pay. For Ex: if investors feel that Egalet is worth a lot, it will most likely be reflected in an inflated Egalet stock quote, and vice versa. However, it must be noted that a company's value must not be equated to its share price. 631156 EGLT shares were traded yesterday, and Egalet stock chart shows that the EGLT stock quote hit a day high of 5.26 and day low of 5. Dividends are usually paid by large stable companies, and typically not by those which are in their rapid growth stages. A company's continuing success is indicated by a steadily increasing dividend payout. To check the historical stock price movement, all time high, and all time low of EGLT, view Egalet stock price history.